[HTML][HTML] Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non …
Y Xu, J Yan, C Zhou, L Wu, H Wang, J Zhao… - European Journal of …, 2023 - Elsevier
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small …
Y Xu, J Yan, C Zhou, L Wu, H Wang, J Zhao… - European Journal of …, 2023 - europepmc.org
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small …
Y Xu, J Yan, C Zhou, L Wu, H Wang… - … journal of cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small …
Y Xu, J Yan, C Zhou, L Wu, H Wang, J Zhao… - European Journal of …, 2023 - ejcancer.com
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small …
Y Xu, J Yan, C Zhou, L Wu, H Wang, J Zhao… - European Journal of …, 2023 - ejcancer.com
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …